alectinib (alecensa) Report issue

Small molecule Orphan Drug FDA Approved FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group. Alectinib is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability. Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance. Alectinib is marketed as Alecensa.   NCATS

Chemistry

  • SMILES: CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O
  • InChIKey: KDGFLJKFZUIJMX-UHFFFAOYSA-N
  • Mol. Mass: 482.63
  • ALogP: 4.77
  • ChEMBL Molecules:
    alectinib  
    alectinib hydrochloride  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$23.2148

United States

$47.1479 - $62.3425
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile | af-802 | alecensa | alectinib | alectinib hcl | alectinib hydrochloride | ch5424802 | ch-5424802 | ro5424802 | ro-5424802 | ro5452802

Organizations (43)

Research & Development (43)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (46)

Approved Indications (1)


 

Carcinoma, Non-Small-Cell Lung

Experimental Indications - Clinical Trial Phases 1-4 (46)


 

Biliary Tract Neoplasms (Phase 2)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Bronchial Neoplasms (Phase 2)

Carcinoma, Bronchogenic (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 4)

Carcinoma, Renal Cell (Phase 2/Phase 3)

Central Nervous System (Phase 2)

Cholangiocarcinoma (Phase 2)

Colonic Diseases (Phase 2)

Colorectal Neoplasms (Phase 2)

Digestive System Diseases (Phase 2)

Digestive System Neoplasms (Phase 2)

Drug Monitoring (Phase 4)

Gastrointestinal Diseases (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Glioblastoma (Phase 1/Phase 2)

Head and Neck Neoplasms (Phase 2)

Healthy Volunteers (Phase 1)

Intestinal Diseases (Phase 2)

Intestinal Neoplasms (Phase 2)

Liver Diseases (Phase 1)

Lung Neoplasms (Phase 4)

Lymphoma (Phase 2/Phase 3)

Lymphoma, Large-Cell, Anaplastic (Phase 4)

Lymphoproliferative Disorders (Phase 2/Phase 3)

Melanoma (Phase 2)

Mutation (Phase 1/Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms ()

Neoplasms by Histologic Type (Phase 2/Phase 3)

Neoplasms by Site (Phase 2/Phase 3)

Neuroblastoma (Phase 2/Phase 3)

Neuroendocrine Tumors (Phase 2)

Oncogenes (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Respiratory Tract Diseases (Phase 2)

Respiratory Tract Neoplasms (Phase 2)

Salivary Gland Neoplasms (Phase 2)

Sarcoma (Phase 2)

Thoracic Neoplasms (Phase 2)

Thyroid Cancer, Papillary (Phase 2)

Thyroid Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 51
  • # of Trial Organizations: 43

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue